WO2005007827A3 - Avian adeno-associated virus vector - Google Patents

Avian adeno-associated virus vector Download PDF

Info

Publication number
WO2005007827A3
WO2005007827A3 PCT/US2004/022614 US2004022614W WO2005007827A3 WO 2005007827 A3 WO2005007827 A3 WO 2005007827A3 US 2004022614 W US2004022614 W US 2004022614W WO 2005007827 A3 WO2005007827 A3 WO 2005007827A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated virus
virus vector
avian adeno
avian
adeno
Prior art date
Application number
PCT/US2004/022614
Other languages
French (fr)
Other versions
WO2005007827A2 (en
Inventor
Carlos Estevez
Pedro Villegas
Original Assignee
Univ Georgia Res Found
Carlos Estevez
Pedro Villegas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found, Carlos Estevez, Pedro Villegas filed Critical Univ Georgia Res Found
Publication of WO2005007827A2 publication Critical patent/WO2005007827A2/en
Publication of WO2005007827A3 publication Critical patent/WO2005007827A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

An avian adeno-associated virus vector for gene transfer to avians, including immunogenic and non-immunogenic peptides/proteins for the generation of immunity, genetically modified organisms, and bioreactors.
PCT/US2004/022614 2003-07-14 2004-07-13 Avian adeno-associated virus vector WO2005007827A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48706503P 2003-07-14 2003-07-14
US60/487,065 2003-07-14

Publications (2)

Publication Number Publication Date
WO2005007827A2 WO2005007827A2 (en) 2005-01-27
WO2005007827A3 true WO2005007827A3 (en) 2005-08-25

Family

ID=34079342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022614 WO2005007827A2 (en) 2003-07-14 2004-07-13 Avian adeno-associated virus vector

Country Status (1)

Country Link
WO (1) WO2005007827A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011040527A1 (en) * 2009-09-30 2011-04-07 国立大学法人帯広畜産大学 TRANSGENIC BIRD CAPABLE OF EXPRESSING α-GALACTOSE EPITOPE, VIRUS, AND VACCINE
WO2021041986A1 (en) * 2019-08-28 2021-03-04 University Of Florida Research Foundation, Incorporated Improved production of recombinant aav using embryonated avian eggs
CN113061625B (en) * 2021-04-25 2023-04-21 华南农业大学 Replication-defective canine parvovirus packaging vector, replication-defective recombinant canine parvovirus, and preparation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136710A1 (en) * 1998-01-12 2002-09-26 The University Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US20030103939A1 (en) * 2001-07-13 2003-06-05 Engelhardt John F. Pseudotyped adeno-associated viruses and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136710A1 (en) * 1998-01-12 2002-09-26 The University Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US20030103939A1 (en) * 2001-07-13 2003-06-05 Engelhardt John F. Pseudotyped adeno-associated viruses and uses thereof

Also Published As

Publication number Publication date
WO2005007827A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2006104615A3 (en) Influenza nucleic acids, polypeptides, and uses thereof
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2004099370A3 (en) NOVEL BACILLUS mHKcel CELLULASE
EP1824971A4 (en) Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2001064920A3 (en) Hybrid expression of neisserial proteins
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
NO20065084L (en) Interferon-alpha polypeptides and conjugates
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
EP2351843A3 (en) Rabies virus vector systems and compositions and methods thereof
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
EP1808180A3 (en) Modified GP 100 and uses thereof
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ATE473238T1 (en) TUBERCULOSIS VACCINE WITH IMPROVED EFFICIENCY
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2006060728A3 (en) Methods and compositions involving lcrv proteins
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
WO2004097001A3 (en) Novel bacillus 029cel cellulase
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
WO2002036627A3 (en) Interferons, uses and compositions related thereto
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2003062453A3 (en) Polycystic kidney disease nucleic acids and proteins
WO2005007827A3 (en) Avian adeno-associated virus vector

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase